There are currently 975 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
Recruiting
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Gender:
Male
Ages:
50 years and above
Trial Updated:
01/23/2023
Locations: Lucid Investigative Site, Birmingham, Alabama
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Rett Syndrome Registry
Recruiting
The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett syndrome experts and by the caregivers of individuals with Rett syndrome. This study will be used to develop consensus based guidelines for the care of your loved ones with Rett s... Read More
Gender:
All
Ages:
Between 0 years and 99 years
Trial Updated:
01/09/2023
Locations: University of Alabama, Birmingham, Alabama
Conditions: Rett Syndrome, Rett Syndrome, Atypical, Genetic Disease, Genetic Diseases, X-Linked, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Neurologic Disorder, Neurodevelopmental Disorders, Nervous System Diseases
Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)
Recruiting
An extension of the PREMOD2 trial, the PREMOD2 Follow-Up trial will evaluate the neurodevelopmental outcomes at 22-26 months corrected age of preterm children who received UCM or DCC. This prospective multi-national randomized controlled trial (RCT) is a two-arm parallel non-inferiority design of two alternative approaches of treatment.
Gender:
All
Ages:
Between 22 months and 42 months
Trial Updated:
11/22/2022
Locations: University of Alabama, Birmingham, Alabama
Conditions: Neurodevelopmental Abnormality
CERENOVUS Neurothrombectomy Devices Registry
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device and CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/19/2022
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Cerebral Stroke
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Breast Cancer
A Study to Monitor Ambulatory Blood Pressure Monitoring in Hypogonadal Men Treated With Nasal Testosterone Gel
Recruiting
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
Gender:
Male
Ages:
Between 18 years and 80 years
Trial Updated:
07/04/2022
Locations: Alabama Clinical Therapeutics, Birmingham, Alabama
Conditions: Hypogonadism
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
Recruiting
This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: University of Alabama at Birmingham School of Medicine, Division of Hematology and Oncology, Birmingham, Alabama
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
Recruiting
Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/03/2022
Locations: 10-105, Birmingham, Alabama
Conditions: Alopecia Areata
TruGraf and TRAC In Pediatrics Study
Recruiting
This is a pilot 3 center prospective study of pediatric renal kidney recipients undergoing protocol biopsies examining the performance of the TruGraf gene expression test in children and adolescents.
Gender:
All
Ages:
Between 1 year and 18 years
Trial Updated:
04/12/2022
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Kidney Transplant Rejection
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: University of Alabama, Birmingham, Alabama
Conditions: End Stage Liver Disease
Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease
Recruiting
The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with primary glomerular disease and persistent proteinuria.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2022
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Glomerular Disease, Proteinuria
ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program
Recruiting
The investigators have previously shown that youth with MS are very inactive, and that vigorous physical activity is associated with higher levels of well-being and lower MS disease activity in youth. Yet, no effective physical activity interventions have been developed for youth with MS to date. The investigators have taken input from youth with MS to create a Smartphone-based app (the ATOMIC - Active Teens with Multiple Sclerosis - App) that provides tailored physical activity information and... Read More
Gender:
All
Ages:
Between 11 years and 21 years
Trial Updated:
03/15/2022
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pediatric Multiple Sclerosis